Literature DB >> 19541645

Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.

Mihaela Lorger1, Joseph S Krueger, Melissa O'Neal, Karin Staflin, Brunhilde Felding-Habermann.   

Abstract

The incidence of brain metastasis is rising and poses a severe clinical problem, as we lack effective therapies and knowledge of mechanisms that control metastatic growth in the brain. Here we demonstrate a crucial role for high-affinity tumor cell integrin alpha(v)beta(3) in brain metastatic growth and recruitment of blood vessels. Although alpha(v)beta(3) is frequently up-regulated in primary brain tumors and metastatic lesions of brain homing cancers, we show that it is the alpha(v)beta(3) activation state that is critical for brain lesion growth. Activated, but not non-activated, tumor cell alpha(v)beta(3) supports efficient brain metastatic growth through continuous up-regulation of vascular endothelial growth factor (VEGF) protein under normoxic conditions. In metastatic brain lesions carrying activated alpha(v)beta(3), VEGF expression is controlled at the post-transcriptional level and involves phosphorylation and inhibition of translational respressor 4E-binding protein (4E-BP1). In contrast, tumor cells with non-activated alpha(v)beta(3) depend on hypoxia for VEGF induction, resulting in reduced angiogenesis, tumor cell apoptosis, and inefficient intracranial growth. Importantly, the microenvironment critically influences the effects that activated tumor cell alpha(v)beta(3) exerts on tumor cell growth. Although it strongly promoted intracranial growth, the activation state of the receptor did not influence tumor growth in the mammary fat pad as a primary site. Thus, we identified a mechanism by which metastatic cells thrive in the brain microenvironment and use the high-affinity form of an adhesion receptor to grow and secure host support for proliferation. Targeting this molecular mechanism could prove valuable for the inhibition of brain metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541645      PMCID: PMC2697113          DOI: 10.1073/pnas.0903035106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Real-time reverse transcription-PCR quantification of vascular endothelial growth factor splice variants.

Authors:  Eleni Zygalaki; Aliki Stathopoulou; Christos Kroupis; Loukas Kaklamanis; Zenon Kyriakides; Dimitrios Kremastinos; Evi S Lianidou
Journal:  Clin Chem       Date:  2005-08       Impact factor: 8.327

Review 2.  Integrin regulation.

Authors:  Mark H Ginsberg; Anthony Partridge; Sanford J Shattil
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

3.  A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells.

Authors:  Luciano Vellon; Javier A Menendez; Ruth Lupu
Journal:  Mol Carcinog       Date:  2006-10       Impact factor: 4.784

Review 4.  The biology of integrins.

Authors:  Dwayne G Stupack
Journal:  Oncology (Williston Park)       Date:  2007-08       Impact factor: 2.990

Review 5.  Breast cancer metastasis to the central nervous system.

Authors:  Robert J Weil; Diane C Palmieri; Julie L Bronder; Andreas M Stark; Patricia S Steeg
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

Review 6.  The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Authors:  Friedegund Meier; Birgit Schittek; Silke Busch; Claus Garbe; Keiran Smalley; Kapaettu Satyamoorthy; Gang Li; Meenhard Herlyn
Journal:  Front Biosci       Date:  2005-09-01

7.  Adaptation of energy metabolism in breast cancer brain metastases.

Authors:  Emily I Chen; Johannes Hewel; Joseph S Krueger; Claire Tiraby; Martin R Weber; Anastasia Kralli; Katja Becker; John R Yates; Brunhilde Felding-Habermann
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

8.  A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.

Authors:  Steve Braunstein; Ksenia Karpisheva; Carolina Pola; Judith Goldberg; Tsivia Hochman; Herman Yee; Joan Cangiarella; Rezina Arju; Silvia C Formenti; Robert J Schneider
Journal:  Mol Cell       Date:  2007-11-09       Impact factor: 17.970

9.  Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src.

Authors:  Stephan Huveneers; Iman van den Bout; Petra Sonneveld; Ana Sancho; Arnoud Sonnenberg; Erik H J Danen
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

Review 10.  Surgical management of brain metastases.

Authors:  Moksha G Ranasinghe; Jonas M Sheehan
Journal:  Neurosurg Focus       Date:  2007-03-15       Impact factor: 4.047

View more
  76 in total

1.  Metastasis as a therapeutic target in prostate cancer: a conceptual framework.

Authors:  Konstantin Stoletov; David Bond; Katie Hebron; Srijan Raha; Andries Zijlstra; John D Lewis
Journal:  Am J Clin Exp Urol       Date:  2014-04

2.  Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIbβ3 and αvβ3 integrins in different manner.

Authors:  Ronit Mor-Cohen; Nurit Rosenberg; Yulia Einav; Ehud Zelzion; Meytal Landau; Wissam Mansour; Yulia Averbukh; Uri Seligsohn
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

3.  Genetic variants associated with colorectal brain metastases susceptibility and survival.

Authors:  S Stremitzer; A S Berghoff; N B Volz; W Zhang; D Yang; S Stintzing; Y Ning; Y Sunakawa; S Yamauchi; A Sebio; S Matsusaka; S Okazaki; D Hanna; A Parekh; A Mendez; M D Berger; R El-Khoueiry; P Birner; M Preusser; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2015-12-22       Impact factor: 3.550

4.  αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Authors:  Anna Sophie Berghoff; Astrid Kerstin Kovanda; Thomas Melchardt; Rupert Bartsch; Johannes A Hainfellner; Bence Sipos; Jens Schittenhelm; Christoph C Zielinski; Georg Widhalm; Karin Dieckmann; Michael Weller; Simon L Goodman; Peter Birner; Matthias Preusser
Journal:  Clin Exp Metastasis       Date:  2014-08-24       Impact factor: 5.150

5.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

6.  Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression.

Authors:  Xiuxing Wang; Briana C Prager; Qiulian Wu; Leo J Y Kim; Ryan C Gimple; Yu Shi; Kailin Yang; Andrew R Morton; Wenchao Zhou; Zhe Zhu; Elisabeth Anne Adanma Obara; Tyler E Miller; Anne Song; Sisi Lai; Christopher G Hubert; Xun Jin; Zhi Huang; Xiaoguang Fang; Deobrat Dixit; Weiwei Tao; Kui Zhai; Cong Chen; Zhen Dong; Guoxin Zhang; Stephen M Dombrowski; Petra Hamerlik; Stephen C Mack; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2018-04-05       Impact factor: 24.633

7.  Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.

Authors:  Qianqian Qiu; Qiongyao Wang; Changxu Deng; Yanqin Sun; Taoliang Chen; Linlang Guo; Fan Zhang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 8.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

9.  Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model.

Authors:  Y Jeffrey Wu; Leslie L Muldoon; Seymur Gahramanov; Dale F Kraemer; Deborah J Marshall; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2012-07-29       Impact factor: 4.130

10.  Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.

Authors:  Ryogo Minamimoto; Amer Karam; Mehran Jamali; Amir Barkhodari; Sanjiv Sam Gambhir; Oliver Dorigo; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.